OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
BALM456

Baumer SA

Medical Equipment, Supplies & DistributionVerified

Baumer SA maintains a conservative capital structure with a debt-to-equity ratio of 0.13, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 2.86, suggesting it can cover short-term obligations but with limited excess capacity. However, the company's free cash flow is negative at -506,000 BRL, and its net cash position is negative after subtracting total debt, signaling potential liquidity constraints. In terms of profitability, Baumer SA's return on equity (ROE) is 2.7%, and its return on assets (ROA) is 1.58%. These figures are below the typical thresholds for high-performing healthcare equipment firms, indicating that the company is not generating strong returns relative to its equity and asset base. The operating margin, calculated as operating income of 4,264,000 BRL on revenue of 36,320,000 BRL, is 11.74%, which is in line with the industry's median but not exceptional. The company's revenue is not segmented by geographic region or product line in the available data, so it is not possible to assess geographic or segment concentration risk. However, the lack of segmentation data suggests that the company may have a relatively undiversified revenue base, which could expose it to regional or product-specific risks. Looking ahead, the company's growth trajectory is not clearly defined in the available data. The absence of specific revenue growth projections or historical growth rates makes it difficult to assess the company's future performance. The capital expenditure of -2,649,000 BRL indicates that the company is investing in its operations, but the negative free cash flow suggests that these investments are not yet generating positive cash returns. The risk assessment for Baumer SA highlights a medium liquidity risk and a low dilution risk. The company's shares outstanding are the same for both basic and diluted shares, indicating no imminent threat of share dilution. However, the negative free cash flow and the negative net cash position after debt suggest that the company may need to raise additional capital in the near term, which could introduce new risks. There are no recent events or filings mentioned in the available data that would significantly impact the company's operations or financial position. The absence of recent transcripts or filings suggests that the company may not be actively communicating with investors or disclosing material developments.

30-day price · BALM4-1.44 (-7.3%)
Low$17.66High$19.74Close$18.19As of13 May, 00:00 UTC
Profile
CompanyBaumer SA
TickerBALM4.SA
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Baumer SA is a medical equipment and supplies company that generates revenue through the distribution and sale of healthcare products and services.

Classification. Baumer SA is classified in the industry "Medical Equipment, Supplies & Distribution" under the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

Baumer SA maintains a conservative capital structure with a debt-to-equity ratio of 0.13, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 2.86, suggesting it can cover short-term obligations but with limited excess capacity. However, the company's free cash flow is negative at -506,000 BRL, and its net cash position is negative after subtracting total debt, signaling potential liquidity constraints. In terms of profitability, Baumer SA's return on equity (ROE) is 2.7%, and its return on assets (ROA) is 1.58%. These figures are below the typical thresholds for high-performing healthcare equipment firms, indicating that the company is not generating strong returns relative to its equity and asset base. The operating margin, calculated as operating income of 4,264,000 BRL on revenue of 36,320,000 BRL, is 11.74%, which is in line with the industry's median but not exceptional. The company's revenue is not segmented by geographic region or product line in the available data, so it is not possible to assess geographic or segment concentration risk. However, the lack of segmentation data suggests that the company may have a relatively undiversified revenue base, which could expose it to regional or product-specific risks. Looking ahead, the company's growth trajectory is not clearly defined in the available data. The absence of specific revenue growth projections or historical growth rates makes it difficult to assess the company's future performance. The capital expenditure of -2,649,000 BRL indicates that the company is investing in its operations, but the negative free cash flow suggests that these investments are not yet generating positive cash returns. The risk assessment for Baumer SA highlights a medium liquidity risk and a low dilution risk. The company's shares outstanding are the same for both basic and diluted shares, indicating no imminent threat of share dilution. However, the negative free cash flow and the negative net cash position after debt suggest that the company may need to raise additional capital in the near term, which could introduce new risks. There are no recent events or filings mentioned in the available data that would significantly impact the company's operations or financial position. The absence of recent transcripts or filings suggests that the company may not be actively communicating with investors or disclosing material developments.
Key takeaways
  • Baumer SA has a conservative capital structure with a low debt-to-equity ratio of 0.13.
  • The company's return on equity (2.7%) and return on assets (1.58%) are below typical thresholds for high-performing healthcare equipment firms.
  • The company's liquidity position is characterized as medium risk, with a current ratio of 2.86.
  • The company's free cash flow is negative at -506,000 BRL, and its net cash position is negative after subtracting total debt.
  • The company's growth trajectory is not clearly defined in the available data.
  • The company has a low dilution risk, with no imminent threat of share dilution.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyBRL
Revenue$36.3M
Gross profit$23.1M
Operating income$4.3M
Net income$4.0M
R&D
SG&A
D&A
SBC
Operating cash flow$5.6M
CapEx-$2.6M
Free cash flow-$506.0k
Total assets$255.6M
Total liabilities$105.7M
Total equity$149.9M
Cash & equivalents$14.8M
Long-term debt$19.2M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$133.8M$11.9M$16.0M$5.2M
FY-3$164.5M$18.2M$5.7M-$1.1M
FY-2$169.9M$21.6M$9.2M$7.0M
FY-1$194.4M$36.0M$31.6M$19.0M
FY0$213.7M$34.7M$18.1M-$46.3M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$228.1M$130.2M$13.0M
FY-3$248.6M$133.5M$8.9M
FY-2$249.9M$144.2M$13.9M
FY-1$286.7M$178.0M$16.9M
FY0$274.8M$153.0M$16.1M
PeriodOCFCapExFCFSBC
FY-4$17.6M-$4.8M$5.2M
FY-3$3.1M-$6.1M-$1.1M
FY-2$23.6M-$5.4M$7.0M
FY-1$31.3M-$7.7M$19.0M
FY0$54.9M-$12.9M-$46.3M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$36.3M$4.3M$4.0M-$506.0k
FQ-6$46.0M$4.8M$7.7M$5.1M
FQ-5$54.2M$9.5M$5.1M-$883.0k
FQ-4$57.9M$17.4M$14.7M$15.3M
FQ-3$49.3M$10.0M$3.5M-$2.0M
FQ-2$57.1M$8.6M$5.1M-$6.9M
FQ-1$55.0M$9.5M$1.4M$4.2M
FQ0$52.4M$6.5M$8.1M-$41.6M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$255.6M$149.9M$14.8M
FQ-6$263.4M$157.9M$12.6M
FQ-5$269.2M$163.0M$11.5M
FQ-4$286.7M$178.0M$16.9M
FQ-3$281.5M$182.6M$17.6M
FQ-2$287.5M$181.5M$16.1M
FQ-1$300.7M$183.0M$14.1M
FQ0$274.8M$153.0M$16.1M
PeriodOCFCapExFCFSBC
FQ-7$5.6M-$2.6M-$506.0k
FQ-6$14.2M-$4.2M$5.1M
FQ-5$23.6M-$5.5M-$883.0k
FQ-4$31.3M-$7.7M$15.3M
FQ-3$10.5M-$2.1M-$2.0M
FQ-2$20.2M-$5.7M-$6.9M
FQ-1$24.2M-$7.7M$4.2M
FQ0$54.9M-$12.9M-$41.6M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$149.9M
Net cash-$4.3M
Current ratio2.9
Debt/Equity0.1
ROA1.6%
ROE2.7%
Cash conversion1.4%
CapEx/Revenue-7.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricBALM4Activity
Op margin11.7%3.9% medp25 -31.3% · p75 14.4%above median
Net margin11.1%2.4% medp25 -30.5% · p75 11.1%above median
Gross margin63.5%46.7% medp25 28.2% · p75 63.1%top quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-7.3%-4.8% medp25 -11.6% · p75 -2.4%below median
Debt / equity13.0%17.9% medp25 2.7% · p75 52.2%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-12 00:51 UTC#f893a74b
Market quoteclose BRL 18.25 · shares 0.00B diluted
no public URL
2026-05-05 06:05 UTC#c47d4f3e
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 11:01 UTCJob: 50272283